Barclays
FULC icon

Barclays’s Fulcrum Therapeutics FULC Stock Holding History

Barclays’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$678K Sell
88,458
-44,083
-33% -$409K ﹤0.01% 2994
2025
Q4 		$1.5M Buy
132,541
+42,925
+48% +$437K ﹤0.01% 3136
2025
Q3 		$824K Sell
89,616
-22,447
-20% -$162K ﹤0.01% 3487
2025
Q2 		$771K Buy
112,063
+29,606
+36% +$158K ﹤0.01% 3506
2025
Q1 		$237K Sell
82,457
-39,613
-32% -$146K ﹤0.01% 3946
2024
Q4 		$574K Sell
122,070
-2,071
-2% -$7.64K ﹤0.01% 3741
2024
Q3 		$443K Buy
124,141
+97,565
+367% +$724K ﹤0.01% 3856
2024
Q2 		$165K Sell
26,576
-44,939
-63% -$340K ﹤0.01% 3678
2024
Q1 		$675K Buy
71,515
+3,330
+5% +$29.7K ﹤0.01% 3403
2023
Q4 		$460K Buy
+68,185
New +$303K ﹤0.01% 3927
2023
Q3 		– Sell
-144,983
Closed -$478K – 4631
2023
Q2 		$478K Buy
144,983
+117,730
+432% +$346K ﹤0.01% 2778
2023
Q1 		$77.7K Buy
27,253
+15,561
+133% +$139K ﹤0.01% 4300
2022
Q4 		$85.1K Buy
11,692
+10,244
+707% +$66.8K ﹤0.01% 4320
2022
Q3 		$12K Sell
1,448
-265
-15% -$1.9K ﹤0.01% 4231
2022
Q2 		$8K Sell
1,713
-21,667
-93% -$212K ﹤0.01% 4686
2022
Q1 		$553K Buy
+23,380
New +$331K ﹤0.01% 2838

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Barclays's FULC Position: Q1 2026 in Review

Barclays reduced its Fulcrum Therapeutics (FULC) stake by 33% in Q1 2026, selling an estimated $409K and leaving 88,458 shares worth $678K. The position accounts for ﹤0.01% of the portfolio, ranked #2994.

Barclays first reported a position in FULC in Q1 2022 and has held it in 16 quarters since. The position peaked at $1.5M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Barclays held 88,458 shares of Fulcrum Therapeutics worth $678K as of Q1 2026.
  • Barclays sold 44,083 Fulcrum Therapeutics shares in Q1 2026, an estimated $409K.
  • Fulcrum Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2994 holding.
  • Barclays first reported a position in Fulcrum Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • Barclays's Fulcrum Therapeutics position peaked at $1.5M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.